What Is Tirzepatide?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. FDA-approved tirzepatide products include Zepbound for chronic weight management and Mounjaro for type 2 diabetes. A selected tirzepatide option is treated as a preference that requires licensed clinician review. Compounded versions are not FDA-approved.

How It Works

Tirzepatide activates both GIP and GLP-1 receptor pathways involved in appetite signaling, satiety, insulin secretion, glucagon regulation, and metabolic response. In weight-management programs, dual incretin activity may support reduced calorie intake and improved metabolic markers in appropriate patients. Tirzepatide is not a guaranteed weight-loss outcome.

What It’s Studied For

Tirzepatide has been studied in type 2 diabetes and chronic weight-management trials. FDA-approved branded tirzepatide has formal labeling for route, dose forms, warnings, and contraindications. Compounded versions do not go through the same FDA review for safety, effectiveness, or quality.

How It May Be Used in a Clinician-Supervised Program

A licensed clinician may consider tirzepatide when a patient's goals, weight history, medical history, current medications, and contraindication profile support use. The provider should review diabetes status, hypoglycemia risk with other medications, history of pancreatitis or gallbladder disease, severe gastrointestinal disease, pregnancy status, and thyroid cancer/MEN2 history.

Preferred Starting Options / Dosing Notes

Many patients begin with a lower starting option so a licensed clinician can evaluate tolerance, medical history, goals, and safety factors before any adjustments are considered. The starting option shown below is informational and reflects available program data, not self-directed dosing instructions. Final medication, dose, frequency, and treatment plan are determined by a licensed clinician.

Safety Considerations

• Gastrointestinal side effects, dehydration, gallbladder disease, and pancreatitis warnings are reported.
• Hypoglycemia may occur when used with insulin or sulfonylureas; kidney injury risk has been associated with dehydration.
• Labeled contraindication for personal/family history of medullary thyroid carcinoma or MEN2 with FDA-approved GLP-1 products.
• Disclose pregnancy plans, breastfeeding, current medications, and prior GLP-1 reactions.
• Compounded versions are not FDA-approved.

Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing.

Frequently Asked Questions